Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AN
Annovis Bio, Inc.
ANVS
Mkt Cap
$42.7M
Volume
617.91K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AN
ANVS
AN
Annovis Bio, Inc.
ANVS
News
·
Annovis to Host Corporate Update Webinar on September 2, 2026
Mkt Cap
$42.4M
Volume
617.91K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Annovis to Host Corporate Update Webinar on September 2, 2026
Annovis Bio (NYSE: ANVS) announced that its pivotal Phase 3 Alzheimer's disease trial has reached full enrollment with 850 patients, exceeding original projections. The company expects top-line data readout and regulatory submissions in 2027, with an open-label extension study beginning in October 2026. The company is also advancing its Parkinson's disease program with ongoing discussions with the FDA.
GlobeNewswire Inc. · Aug 25, 2026
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Bio will present two research presentations at the CTAD conference, highlighting biomarker data for buntanetap in treating Alzheimer's and Parkinson's diseases, focusing on potential disease-modifying therapeutic approaches.
GlobeNewswire Inc. · Nov 24, 2025
Alzheimer’s Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances | DelveInsight
The Alzheimer's disease market is expected to grow significantly between 2025-2034, driven by emerging therapies targeting disease mechanisms and improved diagnostic capabilities, with the US market representing approximately 50% of the total market size.
GlobeNewswire Inc. · Jul 8, 2025
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Annovis Bio, a late-stage clinical drug platform company, will present data from its latest Phase 3 Parkinson's disease and Phase 2/3 Alzheimer's disease studies at the AD/PD™ 2025 conference in Vienna.
GlobeNewswire Inc. · Mar 25, 2025
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight
LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.
GlobeNewswire Inc. · Mar 3, 2025
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.
GlobeNewswire Inc. · Feb 13, 2025
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Annovis Bio, a late-stage clinical drug platform company, announced that its CEO will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference, highlighting the progress of the pivotal Phase 3 trial in early Alzheimer's disease and strategic initiatives toward a New Drug Application for buntanetap.
GlobeNewswire Inc. · Feb 7, 2025
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
Annovis Bio Inc. has announced the start of a pivotal Phase 3 study evaluating its drug candidate buntanetap for the treatment of early Alzheimer's disease. The study aims to assess the safety and efficacy of buntanetap in improving cognition and functional ability in patients.
GlobeNewswire Inc. · Feb 5, 2025
Annovis Bio, Inc. Announces Proposed Public Offering
Annovis Bio, a clinical-stage biopharmaceutical company, announced its intention to offer common stock and warrants in a public offering. The company plans to use the net proceeds for working capital and the continued development of its lead compound, Buntanetap, for the treatment of neurodegenerative diseases.
GlobeNewswire Inc. · Feb 1, 2025
Annovis to Host Year-End Investor Webcast on December 11, 2024
Annovis Bio, a clinical-stage drug platform company, is hosting an investor webcast on December 11, 2024, to provide updates on its Phase 3 studies for Parkinson's and Alzheimer's diseases, regulatory milestones, financial overview, and strategic outlook for 2025.
GlobeNewswire Inc. · Nov 25, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AN
ANVS
Annovis Bio, Inc.
Buy
Sell
Market
Limit
Soon
ANVS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ANVS yet.
Related Tickers
AL
ALXO
—
Earnings